Detalhe da pesquisa
1.
Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
J Clin Pharmacol
; 49(4): 416-22, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19246721
2.
Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers.
Curr Ther Res Clin Exp
; 70(6): 421-38, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24692835
3.
Effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects.
J Clin Pharmacol
; 43(2): 187-92, 2003 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-12616672
4.
Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteers.
J Clin Pharmacol
; 42(2): 215-21, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11831545
5.
Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib.
J Clin Pharmacol
; 47(10): 1342-6, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17656618
6.
Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.
J Clin Pharmacol
; 50(11): 1273-9, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20107202
7.
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Biopharm Drug Dispos
; 28(6): 315-22, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17575559
8.
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
Drug Metab Dispos
; 35(4): 533-8, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17220239